Delivery Order SPE2DB22D3016-SPE2DB25FBAG7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award status. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,622.22 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This is a firm fixed price, non-set-aside competitive award with a completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $14,455.29 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This firm fixed-price contract, with an ultimate completion date of August 5, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $3,405.64 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on June 6, 2025, with a completion date of June 9, 2025. This competitively awarded, firm fixed-price contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $22,877.40 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated SPE2DX and valued at $999,999,999. The delivery location is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $15,472.34. This is a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $26,993.06 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $4,080.45 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on September 19, 2025, with completion scheduled for September 22, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injections on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $6,863.22 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on May 6, 2025, with an ultimate completion date of May 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBAG7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,512.61 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections. The contract was awarded on June 24, 2025, with an ultimate completion date of June 25, 2025, and utilizes firm fixed pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical supplies to federal healthcare systems, particularly supporting military and veteran populations through the Defense Health Agency and related organizations. The company's comprehensive pharmaceutical portfolio includes specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This specific delivery order for Zepbound, a diabetes medication, reflects the company's role in supplying specialized pharmaceutical products through DLA's global pharmaceutical support infrastructure, which serves military healthcare programs worldwide and is planning to transition to next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts in coming years.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 6/24/25 |